Bruton’s Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia

Bacterial infections are a major cause of morbidity and mortality in chronic lymphocytic leukemia (CLL), and infection risk increases in patients treated with the Bruton’s tyrosine kinase (Btk) inhibitor, ibrutinib. Btk and related kinases (like Tec) are expressed in non-leukemic hematopoietic cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Naylor-Adamson, Leigh, Chacko, Anisha R., Booth, Zoe, Caserta, Stefano, Jarvis, Jenna, Khan, Sujoy, Hart, Simon P., Rivero, Francisco, Allsup, David J., Arman, Mònica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667317/
https://www.ncbi.nlm.nih.gov/pubmed/34912339
http://dx.doi.org/10.3389/fimmu.2021.766272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8667317/
https://www.ncbi.nlm.nih.gov/pubmed/34912339
http://dx.doi.org/10.3389/fimmu.2021.766272

Ejemplares similares